Worldwide Clinical Trials: How Global Studies Are Conducted

Global clinical trials are research studies that enroll participants across multiple countries under a coordinated protocol, regulatory strategy, and data management plan. These studies allow sponsors to test medical interventions in diverse populations, accelerate recruitment, and generate evidence that supports regulatory approval in several jurisdictions at once. For students, researchers, and life-science professionals, understanding how these trials are structured requires attention to regulatory harmonization, site selection, contract research organization (CRO) roles, and the practical logistics of running a study across borders.

This article explains the operational framework of multinational clinical research, the regulatory landscape that shapes it, and the key decisions that determine whether a global trial succeeds or fails. It also provides a practical checklist for anyone involved in planning or assessing such studies.

The Scope of Global Clinical Research

Clinical trials conducted across multiple countries have become a standard model for drug and device development. The rationale is straightforward: enrolling participants in several regions simultaneously can shorten recruitment timelines, improve generalizability of results, and provide access to patient populations that may be underrepresented in a single country. However, the complexity of managing different regulatory requirements, ethical standards, and cultural contexts makes these studies substantially more demanding than single-country trials.

The number of global trials including Japan has increased over time, yet it remains much lower than the number including the United States and Europe. Regulatory requirements for clinical trials have been harmonized among Japan, the United States, and Europe, and the quality of clinical trials is kept high in these regions. The approval of Xofluza (baloxavir marboxil) for influenza in Japan under the SAKIGAKE Designation System is an example of a global trial that included Japan. To include Japan in more global trials, stakeholders need to work collaboratively and increase the perception that trials can be conducted appropriately and efficiently in that country. Further measures for better management of trials should also be developed, ultimately leading to improved patient access to new drugs.

This example illustrates a broader point: global trials are not simply larger versions of domestic trials. They require deliberate decisions about which countries to include, how to navigate local regulations, and how to ensure that data collected in different settings remain comparable and credible.

Regulatory Frameworks Across Jurisdictions

Harmonization Efforts and Their Limits

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has produced guidelines that align clinical trial standards across major regions. The ICH Good Clinical Practice (GCP) guidelines establish ethical and quality standards for conducting human subject research. These guidelines are mandatory for all clinical trials in many jurisdictions, regardless of risk classification.

Harmonization does not mean uniformity. Each country or region maintains its own regulatory authority, submission process, and oversight mechanisms. A sponsor must prepare separate regulatory submissions for each participating country, even when the underlying science and protocol are identical. Differences in timelines, documentation requirements, and local expectations can create significant administrative burdens.

The European Union Experience

The European Union has introduced new healthcare regulations aimed at standardizing implementation processes across member states while maintaining high ethical and scientific standards. In clinical research, the simultaneous application of multiple EU regulations to clinical trials poses significant challenges. These regulations often overlap in scope but differ in requirements, creating compliance complexities for healthcare stakeholders in general and for sponsors of clinical trials in particular.

Clinical research programs aimed at optimizing treatment for patients may struggle under the new regulatory environment, which poses additional administrative and financial burdens despite potential benefits for patients and healthcare systems. Coordinated efforts to navigate differing workflows for trials involving both drugs and devices are being addressed at a pan-European level. The European Organisation for the Research and Treatment of Cancer (EORTC) is involved in two high-level initiatives led by the European Commission aimed at tackling challenges in cancer research.

The EU experience demonstrates that regulatory harmonization is an ongoing process. Even within a single economic bloc, differences in national implementation can create friction for sponsors.

The United Kingdom's Evolving Position

The United Kingdom has introduced its own clinical trial regulations, which global pharmaceutical sponsors must analyze strategically. The UK's 2026 Clinical Trial Regulations represent a significant development for sponsors who previously relied on EU frameworks. These regulations affect how trials are authorized, monitored, and reported in the UK, and sponsors must assess whether their existing global trial strategies remain viable.

For sponsors running trials in both the UK and the EU, the divergence in regulatory frameworks adds another layer of complexity. Each jurisdiction requires its own submission, and the timelines for approval may differ.

Low-Risk Trials and Regulatory Burden

Investigator-initiated clinical trials are crucial for improving quality of care for children and pregnant women, as these groups are often excluded from industry-initiated trials. However, trials have become increasingly time-consuming and costly since the EU Clinical Trial Directive entered into force in 2001. This directive made compliance with ICH-GCP guidelines mandatory for all clinical trials, regardless of risk classification.

Compliance with all GCP requirements makes trials very laborious and expensive, while a clear rationale is often missing for low-risk studies. This discourages clinical researchers from starting and carrying out investigator-initiated research. The EU Clinical Trial Regulation (No 536/2014) allows for less stringent rules for low-risk trials, which may make investigator-initiated trials evaluating standard care interventions more feasible. This would allow researchers to obtain evidence on optimal and safe treatments, especially for groups that are underrepresented in medical research.

This tension between rigorous oversight and practical feasibility is a recurring theme in global clinical research. Sponsors must balance the need for high-quality data with the reality that excessive regulatory burden can stifle valuable research.

Site Selection and Country Choice

Criteria for Selecting Countries

Choosing which countries to include in a global trial is one of the most consequential decisions a sponsor makes. The selection process typically considers several factors:

• Regulatory environment: Countries with predictable and efficient regulatory pathways are more attractive to sponsors. Jurisdictions with unclear or changing requirements can delay trial initiation.
• Patient population: The availability of eligible participants is a primary consideration. Some trials require large numbers of patients with specific conditions, which may be easier to find in certain countries.
• Clinical infrastructure: Sites must have the capacity to conduct trials according to GCP standards. This includes trained staff, appropriate facilities, and reliable data management systems.
• Cost: The cost of conducting trials varies significantly across countries. Labor, facility, and regulatory costs all factor into the decision.
• Data quality: Sponsors must be confident that data collected at each site will meet the standards required for regulatory submission.

The Role of Regional Expertise

The example of Japan illustrates how regional expertise and perception can influence site selection. Despite having high-quality clinical trial infrastructure and harmonized regulatory requirements, Japan is included in fewer global trials than the US and Europe. This suggests that factors beyond regulatory alignment, such as perceived efficiency and collaborative relationships, play a role in country selection.

Sponsors should assess each potential country's strengths and limitations honestly. A country with excellent clinical infrastructure but slow regulatory timelines may not be the best choice for a time-sensitive trial. Conversely, a country with rapid regulatory approval but limited site capacity may create bottlenecks during recruitment.

Multi-Regional Trial Design

Multi-regional clinical trials present specific challenges related to the analysis and interpretation of data across regions. Differences in patient demographics, standard of care, and genetic factors can affect treatment responses. Sponsors must plan for these differences during the design phase, including prespecified subgroup analyses and strategies for handling regional heterogeneity.

The design of multi-regional trials also requires attention to the number of participants enrolled in each region. Regulatory authorities in some countries expect to see a sufficient number of local participants to support extrapolation of results to their population. This expectation can influence recruitment targets and site selection.

The Role of Contract Research Organizations

What CROs Do

Contract research organizations (CROs) provide outsourced services to sponsors, ranging from study design and regulatory submission to site monitoring and data management. In global trials, CROs often serve as the operational backbone, coordinating activities across multiple countries and ensuring consistency in trial conduct.

CROs may offer specialized expertise in specific therapeutic areas, geographic regions, or regulatory environments. Sponsors may engage a single CRO for the entire trial or multiple CROs for different functions. The choice depends on the trial's complexity, the sponsor's internal capabilities, and the geographic scope of the study.

Selecting a CRO

When selecting a CRO for a global trial, sponsors should evaluate:

• Experience in relevant regions: A CRO with established relationships with regulatory authorities and clinical sites in the target countries can accelerate trial initiation.
• Quality systems: The CRO's quality management processes must align with GCP requirements and the sponsor's expectations.
• Data management capabilities: Global trials generate large volumes of data from multiple sites. The CRO must have robust systems for data collection, cleaning, and analysis.
• Communication and reporting: Clear communication between the sponsor, CRO, and sites is essential for identifying and resolving issues promptly.

Oversight and Accountability

Sponsors retain ultimate responsibility for the conduct of their trials, even when CROs handle day-to-day operations. This means sponsors must maintain oversight of CRO activities, including regular audits, performance reviews, and escalation procedures for serious issues. The division of responsibilities between sponsor and CRO should be documented clearly in the contract, with defined timelines and quality standards.

Infrastructure and Capabilities Required for Global Trials

Core Infrastructure Components

Conducting a global clinical trial requires substantial infrastructure, including:

• Clinical sites: Hospitals, clinics, and research centers with the capacity to enroll and treat participants according to the protocol.
• Laboratories: Central and local laboratories that can process and analyze biological samples according to standardized procedures.
• Data management systems: Electronic data capture (EDC) platforms, clinical trial management systems (CTMS), and other software that support data collection and monitoring.
• Regulatory expertise: Personnel who understand the regulatory requirements of each participating country and can prepare and submit the necessary documentation.
• Ethics review: Institutional review boards (IRBs) or ethics committees in each country that must approve the trial before enrollment begins.

Capabilities and Capacities

A rapid scoping review of recommendations and regulations has examined the infrastructure, capabilities, and capacities required for clinical trial design and delivery. The review highlights that successful trial delivery depends on more than physical infrastructure. It requires trained personnel, established processes, and the ability to adapt to changing circumstances.

Sponsors should assess whether each potential site has the capacity to meet recruitment targets, the capability to follow the protocol accurately, and the infrastructure to support data collection and participant safety monitoring. This assessment should be documented and reviewed periodically throughout the trial.

Global Data Management

Clinical data management in global trials involves collecting, cleaning, and analyzing data from multiple sites across different countries. Regulations and standards for clinical data management vary across jurisdictions, and sponsors must ensure that their data management practices comply with all applicable requirements.

Key considerations include:

• Data standards: Using common data standards, such as CDISC (Clinical Data Interchange Standards Consortium), facilitates data integration and regulatory submission.
• Language and translation: Case report forms and other documents must be translated into local languages, and translation quality must be verified.
• Data privacy: Different countries have different data protection laws, and sponsors must ensure that participant data is handled in compliance with all applicable regulations.
• Data quality: Consistent data entry and monitoring procedures are essential for producing reliable results.

At a Glance: Key Considerations for Multinational Trials

Practical Workflow for Conducting a Global Trial

Phase 1: Feasibility Assessment

Before committing to a global trial, sponsors should conduct a feasibility assessment to determine whether the study is viable. This assessment should evaluate:

• The availability of eligible participants in each potential country
• The regulatory environment and expected timelines for approval
• The infrastructure and capabilities of potential sites
• The costs associated with conducting the trial in each country
• The competitive landscape, including other trials that may be recruiting similar participants

The feasibility assessment should produce a clear recommendation about which countries to include and which sites to approach.

Phase 2: Protocol Development and Regulatory Submission

The protocol is the central document that governs trial conduct. For global trials, the protocol must be written to accommodate differences in local standards of care, regulatory requirements, and cultural contexts. This may require:

• Including language that allows for local adaptations where appropriate
• Defining procedures for handling protocol deviations
• Specifying how adverse events will be reported in each jurisdiction

Once the protocol is finalized, sponsors must prepare regulatory submissions for each participating country. These submissions typically include the protocol, investigator brochure, informed consent form, and other supporting documents. The content and format of submissions vary by jurisdiction, and sponsors must ensure that each submission meets local requirements.

Phase 3: Site Initiation and Training

After regulatory approval is obtained, sponsors and CROs must initiate each site. This involves:

• Conducting site initiation visits to ensure that staff understand the protocol and procedures
• Providing training on data collection, adverse event reporting, and GCP requirements
• Verifying that the site has the necessary equipment and supplies
• Establishing communication channels between the site, CRO, and sponsor

Site initiation is a critical step for ensuring data quality and participant safety. Sites that are not adequately prepared are more likely to make errors that compromise the trial.

Phase 4: Enrollment and Conduct

During the enrollment and conduct phase, sites recruit participants, deliver the intervention, and collect data. Sponsors and CROs monitor site performance through:

• Regular monitoring visits to verify data accuracy and protocol compliance
• Central monitoring of data trends to identify potential issues
• Ongoing communication with sites to address questions and concerns

Recruitment is often the most challenging aspect of trial conduct. Sponsors should track enrollment against targets and implement corrective actions if recruitment lags. This may involve adding new sites, adjusting recruitment strategies, or revising eligibility criteria.

Phase 5: Data Cleaning and Analysis

Once enrollment is complete and the last participant has finished the study, sponsors must clean and analyze the data. This involves:

• Resolving data queries and discrepancies
• Locking the database to prevent further changes
• Conducting statistical analyses according to the prespecified plan
• Preparing the clinical study report for regulatory submission

Data cleaning in global trials is particularly complex because data may be entered in different languages, formats, and time zones. Sponsors must have robust processes for ensuring data quality throughout the trial, beyond at the end.

Phase 6: Regulatory Submission and Post-Trial Obligations

After the data are analyzed, sponsors submit the results to regulatory authorities in each participating country. The submission package typically includes the clinical study report, statistical analysis plan, and other supporting documents.

Post-trial obligations may include:

• Providing study results to participants and sites
• Publishing the results in peer-reviewed journals
• Continuing to monitor participants for long-term safety outcomes
• Fulfilling any commitments made to regulatory authorities during the approval process

Records and Measurements

Essential Records for Global Trials

Accurate record-keeping is essential for global trials. Sponsors and sites must maintain:

• Regulatory documents: Approvals, correspondence, and submissions for each country
• Site documents: Investigator agreements, delegation logs, and training records
• Participant records: Informed consent forms, medical histories, and adverse event reports
• Data records: Case report forms, data queries, and audit trails
• Monitoring records: Visit reports, follow-up letters, and corrective action plans

These records must be maintained for the duration required by applicable regulations, which can be several years after trial completion.

Measuring Trial Performance

Sponsors should track key performance indicators throughout the trial to identify issues early. Common metrics include:

• Enrollment rate: The number of participants enrolled per site per month
• Screen failure rate: The proportion of screened participants who do not meet eligibility criteria
• Protocol deviation rate: The number and severity of deviations from the protocol
• Data query rate: The number of data queries generated per case report form
• Adverse event reporting timeliness: The time between adverse event occurrence and reporting

These metrics should be reviewed regularly, and sites that are underperforming should receive additional support or be replaced if necessary.

Common Failure Patterns in Global Trials

Underestimating Regulatory Complexity

One of the most common failure patterns is underestimating the time and effort required for regulatory approval in multiple countries. Sponsors may assume that harmonized guidelines mean similar submission requirements, only to discover that each country has unique documentation needs and review timelines. This can delay trial initiation by months.

Poor Site Selection

Selecting sites based on convenience or existing relationships instead of capability can lead to recruitment shortfalls and data quality issues. Sites that lack experience with clinical trials may struggle with protocol compliance, data entry, and adverse event reporting. Sponsors should conduct thorough site assessments and verify that each site has the infrastructure and staff to meet the trial's demands.

Inadequate Translation and Cultural Adaptation

Informed consent forms, patient-facing materials, and case report forms must be translated accurately and adapted to local cultural contexts. Poor translation can lead to misunderstandings, consent issues, and data errors. Sponsors should use qualified translators and have translations reviewed by local experts.

Fragmented Data Management

Global trials generate data from multiple sites, often in different languages and formats. Without robust data management systems and processes, data can become inconsistent, incomplete, or lost. Sponsors should establish clear data standards and quality control procedures before enrollment begins.

Communication Breakdowns

Global trials involve many stakeholders: sponsors, CROs, sites, regulatory authorities, and ethics committees. Communication breakdowns between these groups can lead to delays, errors, and misunderstandings. Sponsors should establish clear communication protocols and ensure that all parties have access to the information they need.

Welfare and Safety Context

Protecting Participant Safety Across Borders

Participant safety is the primary concern in any clinical trial, and global trials introduce additional challenges. Sponsors must ensure that:

• Informed consent is valid: Participants must understand the risks and benefits of the trial in their own language and cultural context. Consent processes must comply with local requirements.
• Adverse events are reported promptly: Reporting requirements vary by country, and sponsors must have systems in place to meet all applicable timelines.
• Data safety monitoring is effective: Independent data safety monitoring boards (DSMBs) should review safety data regularly, regardless of where participants are enrolled.
• Emergency care is available: Sites must have arrangements for providing emergency medical care to participants who experience adverse events.

Ethical Considerations in Low-Income Countries

The offshoring of clinical trials to low-income countries raises ethical concerns that sponsors must address proactively. When pharmaceutical corporations offshore clinical trials, nonconsensual experiments can become foreseeable and not simply the result of aberrant ethical conduct by a few individuals. Offshoring of clinical trials is structured so that experiments can be presented as health care in a unique form of outsourcing from the host country to pharmaceutical corporations.

Assessments of the risks and potential benefits of offshore corporate pharmaceutical trials should systematically include also the hoped-for benefits and the risks of the experimental drug but also the risk that subjects will not have consented, as well as the broader international consequences of nonconsensual experimentation.

Sponsors conducting trials in low-income countries must take extra care to ensure that:

• Consent processes are culturally appropriate and genuinely voluntary
• Participants have access to necessary medical care beyond the trial intervention
• The trial addresses a health need in the host country
• The host country benefits from the research, such as through capacity building or access to the intervention after the trial

Vulnerable Populations

Some global trials involve vulnerable populations, such as children and pregnant women. These groups are often excluded from industry-initiated trials, making investigator-initiated trials essential for improving their care. However, the regulatory burden associated with conducting trials in these populations can be substantial.

Sponsors and investigators working with vulnerable populations must ensure that:

• The trial addresses a genuine need that cannot be met through other research
• The risks to participants are minimized and justified by the potential benefits
• Appropriate safeguards are in place to protect participants who cannot consent for themselves
• The trial is conducted according to the highest ethical and scientific standards

Professional Escalation Criteria

When to Escalate Issues

Sponsors, CROs, and sites should have clear criteria for escalating issues that cannot be resolved at the local level. Escalation is appropriate when:

• Serious adverse events occur: Any serious or unexpected adverse event should be reported to the sponsor and relevant regulatory authorities immediately.
• Protocol deviations are significant: Deviations that affect participant safety or data integrity should be escalated to the sponsor and, if necessary, to regulatory authorities.
• Recruitment is critically behind target: If a site is unable to meet recruitment targets despite support, the sponsor may need to consider replacing the site or adding new sites.
• Data quality issues are systemic: If data quality problems are widespread, the sponsor may need to pause enrollment and implement corrective actions.
• Ethical concerns arise: Any concern about participant consent, safety, or welfare should be escalated immediately.

Escalation Pathways

Sponsors should establish clear escalation pathways before the trial begins. These pathways should specify:

• Who is responsible for identifying and reporting issues
• Who has the authority to make decisions about trial conduct
• How quickly issues must be escalated
• What documentation is required for escalation

The escalation pathway should be communicated to all stakeholders, including sites, CROs, and regulatory authorities where appropriate.

Limitations and Realistic Expectations

What Global Trials Cannot Achieve

Global trials are powerful tools for generating evidence, but they have limitations that sponsors and researchers should acknowledge:

• Generalizability is not automatic: Results from a global trial may not apply equally to all populations. Differences in genetics, environment, and standard of care can affect treatment responses.
• Regulatory approval is not guaranteed: Even a well-conducted global trial may not lead to approval in every country. Regulatory authorities make independent decisions based on their assessment of the evidence.
• Cost and complexity are substantial: Global trials are more expensive and complex than single-country trials. Sponsors must have the resources and expertise to manage this complexity.
• Ethical challenges are ongoing: Ensuring ethical conduct across diverse cultural and regulatory contexts requires continuous attention and vigilance.

The Role of Professional Judgment

The conduct of global clinical trials requires professional judgment at every stage. Regulations and guidelines provide a framework, but they cannot anticipate every situation. Sponsors, investigators, and CROs must use their expertise to make decisions that protect participants, maintain data quality, and advance scientific knowledge.

Professional judgment is particularly important when regulations are ambiguous or when local requirements conflict with global standards. In these situations, sponsors should seek advice from regulatory authorities, ethics committees, and legal experts to ensure that their decisions are appropriate.

Frequently Asked Questions

What is the difference between a global clinical trial and a multi-regional clinical trial?

A global clinical trial enrolls participants in multiple countries across different regions of the world. A multi-regional clinical trial is a specific type of global trial that is designed to support regulatory approval in multiple regions simultaneously, often with prespecified analyses for each region. All multi-regional trials are global, but not all global trials are designed with the same regional analysis objectives.

Why do sponsors conduct clinical trials in multiple countries?

Sponsors conduct trials in multiple countries to accelerate recruitment, access diverse patient populations, and generate evidence that supports regulatory approval in several jurisdictions. Global trials can also reduce costs and improve the generalizability of results. However, these benefits must be weighed against the increased complexity and regulatory burden of conducting trials across borders.

How do regulatory requirements differ across countries?

Regulatory requirements differ in terms of submission formats, review timelines, documentation requirements, and local expectations. While harmonization efforts such as ICH guidelines have aligned many standards, each country maintains its own regulatory authority and approval process. Sponsors must prepare separate submissions for each country and adapt their processes to local requirements.

What is the role of a contract research organization in a global trial?

A contract research organization (CRO) provides outsourced services to sponsors, including study design, regulatory submission, site monitoring, and data management. In global trials, CROs coordinate activities across multiple countries and ensure consistency in trial conduct. Sponsors retain ultimate responsibility for the trial and must maintain oversight of CRO activities.

How do sponsors ensure data quality in global trials?

Sponsors ensure data quality through standardized data collection procedures, central monitoring of data trends, regular site monitoring visits, and robust data cleaning processes. Using common data standards, such as CDISC, facilitates data integration across sites. Sponsors must also address language and translation issues to ensure that data are entered accurately and consistently.

What ethical considerations are unique to global trials?

Global trials raise ethical considerations related to informed consent, cultural differences, vulnerable populations, and the conduct of research in low-income countries. Sponsors must ensure that consent processes are culturally appropriate and genuinely voluntary, that participants have access to necessary medical care, and that the trial addresses a health need in the host country. The risk of nonconsensual experimentation in offshored trials is a particular concern that requires proactive safeguards.

How long does it take to get regulatory approval for a global trial?

The time required for regulatory approval varies significantly by country and by the type of trial. Some countries have expedited pathways for certain types of studies, while others have lengthy review processes. Sponsors should research expected timelines for each country during the feasibility assessment and build buffer time into their project plans.

What should a sponsor do if a site is not meeting recruitment targets?

If a site is not meeting recruitment targets, the sponsor should first assess the reasons for the shortfall. Common causes include restrictive eligibility criteria, competing trials, and inadequate site resources. The sponsor may provide additional support to the site, adjust recruitment strategies, or add new sites. If the site continues to underperform, the sponsor may need to replace it or close it and redistribute participants to other sites.

Related Articles

• Regulatory Genome
• Regulatory Genome
• Regulatory Genome
• Annotation Transcript Selection
• Annotation Transcript Selection

References and Further Reading

• Life, Physical, and Social Science Occupations. U.S. Bureau of Labor Statistics.
• Healthcare Occupations. U.S. Bureau of Labor Statistics.
• O*NET OnLine. U.S. Department of Labor.
• Office of Intramural Training and Education. National Institutes of Health.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.
• Promotion of Japan's participation in global clinical trials.. Drug discovery today, 2019.
• Editorial.. Drug research, 2018.
• Navigating EU clinical trials: Adapting to a new era of regulations.. Journal of cancer policy, 2025.
• Safeguarding clinical trials.. Nature medicine, 2007.
• Multi-regional clinical trials--what are the challenges?. Pharmaceutical statistics, 2010.
• Low-risk trials for children and pregnant women threatened by unnecessary strict regulations. Does the coming EU Clinical Trial Regulation offer a solution?. European journal of pediatrics, 2020.
• Nonconsensual clinical trials: a foreseeable risk of offshoring under global corporatism.. Journal of bioethical inquiry, 2015.
• Klinische Studien bei Kindern - Besonderheiten, Herausforderungen, neue Modelle zur operativen Durchführung.. Drug research, 2018.
• Effect of electro-thumbtack needles on symptoms during high-altitude exposure: a pilot, single-blind, randomized, controlled study.. 2026.
• Diaphragmatic Ultrasound Parameters as Predictors of Weaning Success in Cervical Spinal Cord Injury.. 2026.
• Rationale, Design, and Experiences from the Vanguard Phase of the Bariatric Surgery for the Reduction of Cardiovascular Events (BRAVE) Trial.. 2026.
• Global governance, flexible regulation and clinical trials in regenerative medicine in the United Kingdom and the European Union. Physis, 2020.
• The UK’s 2026 Clinical Trial Regulations: A Strategic Analysis for Global Pharmaceutical Sponsors. Therapeutic Innovation and Regulatory Science, 2026.
• Overview of global clinical data management regulations and standards. Yaoxue Xuebao, 2015.
• Infrastructure, capabilities, and capacities required for clinical trials design and delivery: A rapid scoping review of recommendations and regulations. Wellcome Open Research, 2025.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.